Glenmark Pharma Releases FY25-26 Sustainability Report

Glenmark Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, detailing its performance across environmental, social, and governance (ESG) parameters. The company reported a standalone turnover of INR 84,400.99 million (approximately INR 8,440 crore) for the full year.

Export revenue stood at INR 48,943.34 million, contributing 57.99% to the total turnover, underscoring the company's global market presence in over 80 countries. Glenmark's Net Worth as of March 31, 2026, was reported at INR 2,41,503.24 million.

Reader Takeaway: Strong export reliance; detailed ESG disclosures add transparency.

What just happened

Glenmark Pharmaceuticals has submitted its Business Responsibility and Sustainability Report (BRSR) for the fiscal year ending March 2026. This report is a mandatory disclosure under SEBI regulations, offering insights into the company's operations beyond financial results.

Why this matters

The BRSR filing provides investors with crucial information on Glenmark's commitment to sustainability, environmental impact, and corporate governance. It reflects the company's efforts to align its operations with Environmental, Social, and Governance (ESG) principles, which are increasingly important for long-term business value.

The backstory

Glenmark Pharmaceuticals is a global pharmaceutical company with a focus on developing and marketing innovative products. The company operates 8 manufacturing plants in India and 3 internationally, serving markets across the globe. The BRSR filing is a continuation of its commitment to transparency in non-financial reporting.

What changes now

This filing does not directly alter the company's operational structure or immediate financial performance but enhances its corporate disclosure. Investors can now assess the company's ESG performance against its stated goals and industry benchmarks.

Risks to watch

While the report highlights positive ESG initiatives like Zero Liquid Discharge (ZLD) efforts, reliance on exports (57.99% of turnover) could pose risks related to geopolitical factors or currency fluctuations in key international markets. The company also noted that ZLD is not yet implemented across all facilities.

Peer comparison

Glenmark's detailed environmental disclosures, including energy consumption (5,84,284 GJ) and CO2 emissions (Scope 1: 11,797 MT CO2e, Scope 2: 73,170 MT CO2e), allow for comparison with other pharmaceutical companies that are also filing their BRSR reports. Its adherence to occupational health and safety standards, with seven sites holding ISO 45001:2018 certification, is a positive indicator.

Context metrics

• Standalone Turnover (FY25-26): INR 84,400.99 Mn
• Export Revenue (FY25-26): INR 48,943.34 Mn (57.99% of turnover)
• Total Energy Consumption (FY25-26): 5,84,284 GJ
• Scope 1 Emissions (FY25-26): 11,797 metric tons CO2e
• Scope 2 Emissions (FY25-26, market-based): 73,170 metric tons CO2e
• Water Withdrawal (FY25-26): 5,46,033 kilolitres
• Total Employees (Year End): 12,708
• Total Workers (Year End): 5,074

What to track next

Investors should monitor Glenmark's progress in achieving its sustainability targets, particularly in expanding ZLD initiatives. Continued growth in export markets and management's strategic response to geopolitical or economic shifts affecting these regions will also be key areas to watch.